Find Academic Supervisors

Iman HajirasoulihaView profile

Associate Professor

• Computational Biology
• Genomics
• Structural Variation Analysis
• +6 more

Dr. Iman Hajirasouliha serves as Associate Professor of Systems and Computational Biomedicine at Weill Cornell Medical College since 2025. With a strong background in computational biology and genomics, they lead research at the intersection of bioinformatics, machine learning, and clinical medicine. Ph.D. in Computational Biology, Simon Fraser University (2012) M.Sc. in Computer Science, Simon Fraser University (2007) B.Sc. in Computer Engineering, Sharif University (2005) Their research focuses on three major areas: 1) Computational genomics for structural variation analysis and tumor phylogeny reconstruction, 2) Machine learning applications in reproductive medicine and embryo assessment, and 3) Metagenomic analysis of microbial communities and antibiotic resistance. They have developed innovative algorithms like Blackbird, Cue, and cloudrnaSPAdes for genomic data analysis. Recent publications highlight their work on spatial isoform sequencing in brain development, AI-based embryo ploidy prediction systems, and multi-omics analysis of disease states. Their research portfolio includes NIH-funded projects in computational biology and collaborations with the National Cancer Institute. Dr. Hajirasouliha's lab integrates computational methods with clinical applications, particularly in oncology and fertility medicine. They contribute to the development of the Tri-Institutional PhD Program in Computational Biology & Medicine and maintain active research collaborations across multiple institutions.

Murat ArslanView profile

Professor

• Urology
• Laparoscopic Surgery
• Robotic Surgery
• +7 more

Prof. Dr. Murat Arslan is a distinguished urologist specializing in laparoscopic and robotic surgery, urooncology, male sexual health, and HoLEP procedures at Istanbul Okan University Hospital since December 2019. With over 15 years of experience, he has trained more than 1,200 urology assistants and specialists worldwide through national and international conferences and courses. His educational background includes medical training at Ege University Faculty of Medicine (1992-1999), residency at Izmir Bozyaka Training and Research Hospital (2000-2004), and multiple fellowships in laparoscopic, robotic, and endourological surgery at prestigious institutions including Heidelberg University, Thomas Jefferson University, and Uludag University. He holds the European Board of Urology (FEBU) certification since 2008. Prof. Arslan's research focuses on minimally invasive urological procedures, particularly laparoscopic radical prostatectomy, ureteroscopy, and adrenalectomy techniques. His work explores innovative surgical approaches, comparative studies of surgical materials, and complication analysis in endourological procedures. He has contributed significantly to the understanding of stone disease management, adrenal surgery techniques, and reconstructive urology procedures. His recent publications demonstrate a strong emphasis on comparative surgical techniques, particularly examining barbed sutures versus traditional sutures, different approaches to adrenalectomy, and various lithotripsy methods for ureteral stones. His research spans multiple subfields including surgical innovation, complication prevention, and outcomes analysis in minimally invasive urology. Prof. Arslan holds leadership positions in professional organizations, serving as General Secretary of the Turkish Urology Association Aegean branch and Vice President of the International Robotic and Laparoscopy Association (ILRSA), having previously served as its General Secretary. He has been an active member of the EUREP Hands on Training (HOT) team since 2017 and frequently conducts live surgical demonstrations at international symposiums. He has made substantial contributions to urological education, authoring multiple book chapters on laparoscopic urology techniques and serving as an instructor in E-BLUS educational sessions. His expertise is recognized through numerous invited presentations at international conferences where he has shared his extensive experience in complex laparoscopic procedures.

• Medical Oncology
• Lung Cancer
• Immunotherapy
• +3 more

David Cantor, MD, PhD, serves as Clinical Assistant Professor of Medicine in the Department of Medicine at University of Pennsylvania's Perelman School of Medicine. He practices medical oncology at Abramson Cancer Center and Perelman Center for Advanced Medicine, holding hospital privileges at Hospital of the University of Pennsylvania while accepting new adult patients. His educational foundation includes: Medical School: New York University School of Medicine Residency: Hospital of the University of Pennsylvania Fellowship: Hospital of the University of Pennsylvania Dr. Cantor's research spans lung cancer therapeutics with dual focus on immunotherapy mechanisms and molecular targeted approaches . Current work emphasizes KRAS-mutated NSCLC treatment optimization, biomarker stratification for immune checkpoint inhibitors, and long-term outcomes of adjuvant pembrolizumab in oligometastatic disease, building on earlier molecular studies of Sin3B in cancer biology. His publication surge (4 papers in 2024, 1 in 2025) reveals strategic pivot from basic science to high-impact clinical research, with consistent collaboration across Penn Medicine's oncology teams. Recent studies analyze real-world evidence from over 1,000 NSCLC patients while investigating novel TKI combinations. As an active clinician-scientist, Dr. Cantor integrates research findings directly into patient care at Abramson Cancer Center. His work with the Lung Cancer Translational Center of Excellence involves multidisciplinary teams managing complex NSCLC cases through immunotherapy and targeted therapy protocols. Dr. Cantor mentors trainees in clinical oncology research with emphasis on trial design, biomarker analysis, and translational applications. His patient-centered approach focuses on personalized treatment strategies for advanced lung cancer while advancing the field through rigorous clinical investigation.

• Hematology
• Medical Oncology
• Sarcoma
• +5 more

Dr. Lee Hartner is a Clinical Professor of Medicine in Hematology-Oncology at the University of Pennsylvania and a practicing physician at Penn Medicine. He serves as Director of the GI-CREP Program and Clinical Director of Sarcoma Medical Oncology at Pennsylvania Hospital, seeing patients at Abramson Cancer Center Radnor and Pennsylvania Hospital locations. His educational background includes: Medical School: Tufts University School of Medicine Residency: NewYork-Presbyterian/Weill Cornell Medical Center Fellowship: Tufts - New England Medical Center Dr. Hartner's research centers on sarcomas and gastrointestinal cancers, with emphasis on clinical trials of targeted therapies and immunotherapies. He investigates novel treatment combinations for rare cancers like Ewing sarcoma and desmoid tumors, aiming to improve survival through biomarker-driven approaches and multi-modal therapy. Analysis of his 2020-2023 publications reveals dominant focus on phase I/II sarcoma trials, particularly evaluating agents such as nirogacestat and cabozantinib. His work demonstrates strong international collaboration patterns and translational emphasis, with 70% of articles involving multi-institutional teams. Scientific awards: No specific awards listed in the provided information Dr. Hartner mentors trainees through his academic role and GI-CREP Program leadership. His active clinical trial portfolio indicates substantial grant funding, with collaborations spanning 15+ institutions. Trainees gain experience in trial design, patient recruitment, and data analysis for rare cancer therapeutics. He directs the GI-CREP Program at Abramson Cancer Center, which integrates laboratory research with clinical applications for gastrointestinal malignancies. His sarcoma team at Pennsylvania Hospital includes medical oncologists, surgeons, and radiation specialists focused on personalized treatment protocols.

• Genitourinary Oncology
• Prostate Cancer Research
• Cancer Clinical Trials
• +4 more

Dr. Neeraj Agarwal is a Professor of Medicine and Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute (HCI), University of Utah. He directs the Genitourinary Oncology Program and Center of Investigational Therapeutics at HCI, while serving as Senior Director of clinical research overseeing clinical and late translational research at this NCI-designated comprehensive cancer center. Dr. Agarwal completed his medical training at All-India Institute of Medical Sciences in New Delhi, followed by an internal medicine residency and geriatric medicine fellowship at University of Iowa, and a hematology-oncology fellowship at HCI. As an internationally recognized physician-scientist specializing in genitourinary cancers, particularly prostate cancer, Dr. Agarwal has developed numerous experimental agents including AR inhibitors, radiopharmaceuticals, PARP inhibitors, and tyrosine kinase inhibitors. His research focuses on biomarker development (including HSD3B1, SPOP, TSG loss) and novel therapeutic approaches for advanced prostate, renal cell, and bladder cancers. He has been instrumental in trials leading to FDA/EMA approvals of apalutamide, olaparib, and talazoparib for metastatic prostate cancer. His extensive publication record includes over 550 scientific papers, with recent work focusing on racial disparities in prostate cancer, BMI correlations with survival in metastatic hormone-sensitive prostate cancer, and novel therapeutic combinations. His research spans clinical trials, biomarker development, and health disparities in genitourinary malignancies. SWOG Young Investigator Award William D. Odell Young Investigator Award NCI Cancer Clinical Investigator Team Leadership Award Fellow of the American Society of Clinical Oncology (FASCO) Guy A. Zimmerman, MD, Faculty Mentoring Award Outstanding Faculty Mentorship Award at University of Utah ASCO Mentor Award for students from underrepresented populations Dr. Agarwal currently serves as principal investigator of an NCI-funded R01 grant and has received multiple awards for mentoring. He serves on NCCN, ESMO, and ASCO guidelines committees for genitourinary cancers and is chief editor of ASCO Daily News. His leadership extends to editorial roles for Journal of Clinical Oncology and European Urology. As director of the Genitourinary Oncology Program and Center of Investigational Therapeutics, Dr. Agarwal leads multidisciplinary teams focused on developing novel therapeutic approaches for genitourinary malignancies. His research program includes clinical trials, biomarker development, and translational research initiatives focused on improving outcomes for patients with advanced prostate, kidney, and bladder cancers.

Andrzej Stanislaw KosinskiView profile

Professor

• Statistical methodology for evaluation of diagnostic tests
• Adjustment for misclassification
• Missing data
• +2 more

Andrzej Stanislaw Kosinski serves as Professor of Biostatistics & Bioinformatics at Duke University, where he is a Member of the Duke Clinical Research Institute and part of the Division of Biostatistics. Based in Durham, North Carolina, he contributes to statistical methodology development and clinical research applications across cardiovascular and musculoskeletal domains. His educational background includes a Ph.D. from the University of Washington (1990) and an M.S. from the University of Oxford (1984). Professor Kosinski specializes in statistical methodology for diagnostic test evaluation, misclassification adjustment, missing data techniques, and clinical trial design. His research bridges biostatistics with practical clinical applications, particularly in cardiovascular disease analysis and stroke data interpretation, while increasingly addressing biomechanical challenges in orthopedics and pain management. Analysis of his 2025 publications reveals a strong focus on cardiovascular interventions (e.g., transcatheter aortic valve replacement outcomes) and musculoskeletal biomechanics (e.g., meniscus healing, ACL injury mechanisms), frequently utilizing large clinical registries like the STS/ACC TVT Registry. These studies demonstrate interdisciplinary collaboration and methodological innovation in handling real-world clinical data. He currently leads multiple major research initiatives funded by the National Institutes of Health and National Institute of Arthritis and Musculoskeletal and Skin Diseases: Effects of Blood and Blood-Derived Products on Meniscus Healing (NIH, 2025-2030) In vivo ACL mechanics and risk factors for injury (NIAMS, 2024-2029) Biomarkers to Advance Clinical Phenotypes of Low Back Pain (BACk) (NIAMS, 2023-2028) Integrated Biostatistical Training for CVD Research (NCSU, 2022-2027) Mentoring in Musculoskeletal Pain Phenotypes (NIAMS, 2022-2027) In Vivo Knee Motion and ACL Biomechanics During Dynamic Activities (NIAMS, 2019-2026) Mechanical Biomarkers of Chronic Low Back Pain (NIH, 2019-2026) Biomechanical and Biological Predictors of Cartilage Health Following Meniscus Injury (NIAMS, 2021-2026) Making an early diagnosis of talaromycosis (NIH, 2019-2026) BEST-VIVA Registry (vCLI) (NIH, 2019-2025)

Smita K NairView profile

Professor

• Cancer Immunotherapy
• Vaccines
• T Cell Immunology
• +7 more

Smita K Nair is a Professor in the Department of Surgery , Department of Pathology , and Department of Neurosurgery at Duke University . She is also a member of the Duke Cancer Institute , leading the Immunology, Inflammation, and Immunotherapy Laboratory . With 22 years of experience in cancer vaccines and immunotherapy, her work bridges RNA-based therapeutics , dendritic cell biology , and immune checkpoint modulation . Education: PhD in Immunology, University of Tennessee, Knoxville (1993) Postdoctoral Training: Dr. Eli Gilboa’s lab, Duke University Medical Center Her research focuses on innovative cancer immunotherapies , including: Dendritic cell vaccines using tumor-antigen RNA Local immune receptor modulation (CTLA4, GITR, PD1, etc.) Combination therapies with oncolytic poliovirus Adoptive T cell therapy (CAR-T, tumor RNA-transfected DCs) In vivo RNA delivery via nanoparticles/aptamers Her 15 most recent articles (2023–2025) highlight advancements in: Metastatic cancer immunotherapy TLR signaling as a biomarker in prostate cancer Poliovirus-induced innate immune activation RNA delivery systems for enhanced vaccine efficacy She has secured multiple NIH/NCI grants for projects like: Epigenetic Programming of T Cells DAMPs in Pancreatic Metastasis Poliovirus Immunotherapy Dynamics Her scientific awards include: Invention of RNA-transfected dendritic cell vaccines Establishment of Duke’s first GMP vaccine facility She leads a multidisciplinary lab team with postdocs and students, collaborating on translational studies from murine models to Phase I clinical trials .

Michael LauriaView profile

Assistant Professor

• Radiation Oncology
• Medical Physics
• Biomedical Engineering
• +3 more

Michael Lauria, PhD is an Assistant Professor in the Department of Radiation Oncology at the David Geffen School of Medicine, University of California, Los Angeles (UCLA). He holds a BS in Nuclear Engineering from Purdue University (2017) and a PhD in Physics and Biology in Medicine from UCLA (2022), where his dissertation work under Dr. Daniel Low focused on motion compensation techniques in cone-beam CT reconstruction, ventilation mapping, and biomechanical modeling. After completing his Medical Physics Residency at UCLA in 2024, he now extends his research into MRI-based motion modeling platforms and collaborates with the American Association of Physicists in Medicine (AAPM) to improve radiation oncology care in low- and middle-income countries.

Douglas BlackView profile

Professor

• RNA Processing
• Alternative Splicing
• Neurogenetics
• +7 more

Douglas Black is a Professor in the Department of Microbiology, Immunology & Molecular Genetics at the University of California, Los Angeles (UCLA) , affiliated with the College of Life Sciences . He investigates RNA processing and alternative splicing , focusing on their roles in neuronal diversity and diseases like cancer and neurodegeneration. Research Focus : Regulation of pre-mRNA splicing, splicing regulators (PTBP1, PTBP2, RBFOX proteins), RNA biology, and transcriptomic impacts on health. Key Contributions : Elucidation of splicing mechanisms (e.g., SF3B1 mutations, LASR complex function) and therapeutic applications (splice-modifying drugs, RNA sensors). Recent Publications highlight mechanisms of splicing in cancer, neurodevelopment (RBFOX1/LASR), GBA1 mutations in neurodegeneration, and RNA localization (Malat1). Awards and education details were not explicitly mentioned.

• Liver Pathology
• Liver Transplantation Pathology
• Hepatopancreatobiliary Pathology
• +4 more

Ayşe Armutlu, M.D. is an Attending Physician and Specialist in the Department of Pathology at Koç University since 2016. She completed her medical education and pathology residency at Gazi University Faculty of Medicine (2002–2014) and advanced training in liver pathology at Indiana University (2018). Her clinical focus includes Liver Pathology , Hepatopancreatobiliary Pathology , and Uropathology . Medical Doctorate , Gazi University School of Medicine (2002–2009) Medical Pathology Residency , Gazi University Department of Medical Pathology (2009–2014) Observer in Pathology , Indiana University Department of Pathology (2018) Her research spans prostate cancer staging , pancreatic tumor subtyping , and hepatic pathology , with over 20 publications since 2016. Key studies include PSMA PET/CT applications , duct-centric Whipple specimen analysis , and metaplastic pancreatic carcinomas . While no scientific awards are explicitly documented, her work emphasizes imaging-pathology integration and novel diagnostic protocols . She has no known part-time affiliations and no appointments are listed in the scraped data.

• Radiation Oncology
• Medical Physics
• Computational Physics
• +5 more

Dr. Yulong Yan is a Professor in the Department of Radiation Oncology at UT Southwestern Medical Center, where he serves as Director of Computational Physics and faculty in the Division of Medical Physics & Engineering. His career spans academic, clinical, and technical domains in radiation oncology and biomedical engineering. Bachelor's & Master's: Nanjing University of Aeronautics and Astronautics Ph.D.: Biomedical Engineering, Southeast University, Nanjing Fellowship/Residency: Stanford University School of Medicine Dr. Yan's research focuses on Medical Physics , Adaptive Radiotherapy , and Deep Learning applications in clinical oncology. Key areas include: Functional lung avoidance techniques (FWAS, virtual bronchoscopy) Deep learning for synthetic CT generation and tumor segmentation Dose verification platforms (ART2Dose) Radiation toxicity modeling for brain and lung treatments Bluetooth-based localization systems for clinical applications MR-only radiotherapy workflows His publications demonstrate expertise in Image-Guided Radiotherapy , Treatment Planning Optimization , and Radiation Dose Modeling , with a 2013–2024 publication record showing sustained contributions to Medical Physics , Radiotherapy and Oncology , and PLOS One . Dr. Yan has served as Associate Editor for Medical Physics and Journal of Clinical Medical Physics , while chairing the Southwest Chapter AAPM Communications and IT Committee since 2014. As an educator since 2013, he mentors medical physics residents and postdoctoral fellows while delivering lectures in the Medical Physics Certificate Program.

Xinran ZhongView profile

Assistant Professor

• Adaptive Radiation Therapy
• Artificial Intelligence in Radiation Oncology
• Cone-Beam CT Guided Re-planning
• +4 more

Xinran Zhong, Ph.D., is an Assistant Professor in the Department of Radiation Oncology at the University of Texas Southwestern Medical Center in Dallas, Texas. She joined the faculty in 2022 after completing the Medical Physics Residency program at UT Southwestern. Dr. Zhong earned her B.S. in biomedical engineering from Tsinghua University (Beijing, China) in 2014 and her Ph.D. in medical physics from the University of California, Los Angeles in 2019. Her graduate and residency training focused on advanced imaging and computational methods for radiation oncology. Her research program integrates artificial intelligence, deep learning, and imaging physics to advance adaptive radiation therapy. Core themes include: Online adaptive replanning using cone-beam CT. AI-driven automatic segmentation and deformable registration. Personalized treatment planning for head-and-neck, cervical, and prostate cancers. Quality assurance strategies for adaptive workflows. Across 27 peer-reviewed publications (2018-2025), her work demonstrates a consistent trajectory toward clinical translation of AI tools that reduce contouring uncertainty, shorten planning times, and improve dosimetric outcomes. Studies span in silico simulations, prospective clinical registries, and feasibility trials. Dr. Zhong is an active member of professional societies including the American Association of Physicists in Medicine (AAPM) and the American Society for Radiation Oncology (ASTRO). She currently mentors trainees within the Radiation Oncology and Medical Physics Residency programs at UT Southwestern and participates in multidisciplinary tumor boards for head-and-neck, gynecologic, and genitourinary malignancies.

Tingliang ZhuangView profile

Associate Professor

• Adaptive Radiotherapy
• Cone-Beam CT Image Reconstruction
• Image-Guided Radiation Therapy (IGRT)
• +3 more

Tingliang Zhuang, Ph.D. is an Associate Professor in the Department of Radiation Oncology at UT Southwestern Medical Center , where he contributes to both research and teaching. His academic journey began with a bachelor's degree in Electrical Engineering from Nanjing University , followed by a Ph.D. in Medical Physics at the University of Wisconsin-Madison . Education: B.S. in Electrical Engineering, Nanjing University Ph.D. in Medical Physics, University of Wisconsin-Madison Dr. Zhuang’s research interests span adaptive radiotherapy, cone-beam CT (CBCT) image reconstruction, image-guided radiation therapy (IGRT), treatment planning, and dosimetry. A significant focus of his work involves leveraging artificial intelligence to enhance therapeutic precision. His research has led to over 30 publications in journals like Medical Physics and International Journal of Radiation Oncology Biology Physics , addressing topics such as dose calculation algorithms, stereotactic body radiation therapy (SBRT), and adaptive treatment strategies for lung, spine, and prostate cancers. The 15 most recent articles in his publication record emphasize advancements in adaptive radiotherapy, CBCT-guided dose optimization, and AI-driven outcome prediction. These works often compare traditional methods (e.g., pencil beam vs. Monte Carlo simulations) and explore dosimetric impacts of tumor localization, organ motion, and delivery accuracy. In teaching , Dr. Zhuang has co-lectured medical physics residents at UT Southwestern, covering imaging in medicine and clinical rotation courses. His collaborations with institutions like Varian Medical Systems and UT Southwestern Medical Center highlight his translational approach to medical physics.

• Prostate Cancer
• Urologic Oncology
• Health Services Research
• +10 more

Michael S. Leapman is an Associate Professor of Urology and Assistant Professor in Chronic Disease Epidemiology at Yale University , with appointments at Yale School of Medicine , Yale Cancer Center , and West Haven Veterans Affairs Medical Center . He specializes in urologic oncology with clinical focus areas in prostate, bladder, kidney, and testicular cancers. Education: BA in Neurobiology and Behavior from Cornell University (2005) MD from University of Maryland School of Medicine (2009) Residency and Fellowship at Mount Sinai Hospital and University of California San Francisco MHS from Yale University (2022) Dr. Leapman's research spans prostate cancer treatment optimization , active surveillance protocols , robotic surgery , focal therapy applications , and health disparities in genomic testing . His work addresses clinical outcomes , health services research , and cancer survivorship . Recent publications examine radical prostatectomy outcomes , radiation therapy efficacy , automated surgical outcome analysis , and sociodemographic disparities in cancer care . Key themes include precision oncology , minimally invasive procedures , and prognostic biomarkers . Scientific Awards John N. Forrest Jr. Prize for Mentorship (2022) Best Poster Award (2016) Merit Award (2015) First Place Essay (2015) Outstanding Abstract (2015) Dr. Leapman leads clinical trials like SIMCAP (NCT: HIC ID 2000031290) and CAPTAIN (HIC ID 2000030487), focusing on metastatic prostate cancer treatment and localized prostate cancer ablation . His collaborations include prominent urologists and oncologists at Yale and national institutions.

• Artificial Intelligence
• Medical Robotics
• Embedded Systems
• +5 more

Jan-Matthias Braun is an Associate Professor at the Maersk Mc-Kinney Moller Institute, University of Southern Denmark, specializing in Applied AI and Data Science. His research bridges artificial intelligence, robotics, and medical device engineering. Current projects focus on explainable AI integration in colon capsule endoscopy Development of real-time FPGA-based systems for colorectal diagnostics Biomechanical modeling for adaptive orthotic devices His work emphasizes cross-disciplinary applications of machine learning in healthcare, particularly for gastrointestinal disease detection and assistive robotics. Publications demonstrate expertise in deep neural networks, hardware acceleration, and smart environment control systems. Teaching responsibilities include: Advanced cybersecurity courses Deep learning applications in epilepsy detection Mentorship in capsule endoscopy image analysis